The University of Chicago Header Logo

Connection

Mark Lingen to Precancerous Conditions

Back to Details
This is a "connection" page, showing publications Mark Lingen has written about Precancerous Conditions.
Mark Lingen
Connection Strength
4.983
Precancerous Conditions
  1. Biological and Molecular Biomarkers in Oral Potentially Malignant Disorders and Oral Cavity Squamous Cell Carcinoma-Innovation and Insights. Dent Clin North Am. 2025 Jul; 69(3S):e1-e33.
    View in: PubMed
    Score: 0.823
  2. CD34 and a smooth muscle actin distinguish verrucous hyperplasia from verrucous carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Apr; 117(4):477-82.
    View in: PubMed
    Score: 0.359
  3. Validation of LOH profiles for assessing oral cancer risk. Cancer Prev Res (Phila). 2012 Sep; 5(9):1075-7.
    View in: PubMed
    Score: 0.328
  4. Genetics/epigenetics of oral premalignancy: current status and future research. Oral Dis. 2011 Apr; 17 Suppl 1:7-22.
    View in: PubMed
    Score: 0.298
  5. Screening for oral premalignancy and cancer: what platform and which biomarkers? Cancer Prev Res (Phila). 2010 Sep; 3(9):1056-9.
    View in: PubMed
    Score: 0.286
  6. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 2008 Jan; 44(1):10-22.
    View in: PubMed
    Score: 0.232
  7. Pattern-Anchored Diagnosis of Oral Epithelial Dysplasia: A Position Paper From COST Action INTERCEPTOR Working Group 2. Head Neck Pathol. 2026 Sep 03; 20(1).
    View in: PubMed
    Score: 0.217
  8. Living evidence-informed guideline on the early detection of oral squamous cell carcinoma and potentially malignant disorders: Light-based adjuncts to determine the need for biopsy, Version 2026 1.0. J Am Dent Assoc. 2026 Sep; 157(9):968-979.
    View in: PubMed
    Score: 0.213
  9. Light-based adjuncts to determine the need for biopsy for early detection of oral squamous cell carcinoma and potentially malignant disorders: An evidence summary of a living systematic review, Version 2026 1.0. J Am Dent Assoc. 2026 Sep; 157(9):980-992.
    View in: PubMed
    Score: 0.213
  10. Living evidence-informed guideline on the early detection of oral squamous cell carcinoma and potentially malignant disorders: Vital staining adjuncts to determine the need for biopsy, Version 2026 1.0. J Am Dent Assoc. 2026 Jun; 157(6):576-587.
    View in: PubMed
    Score: 0.211
  11. Vital staining adjuncts to determine the need for biopsy for early detection of oral squamous cell carcinoma and potentially malignant disorders: An evidence summary of a living systematic review, Version 2026 1.0. J Am Dent Assoc. 2026 Jun; 157(6):588-601.
    View in: PubMed
    Score: 0.211
  12. Living evidence-informed guideline on the early detection of oral squamous cell carcinoma and potentially malignant disorders: Cytology adjuncts to determine the need for biopsy, Version 2026 1.0. J Am Dent Assoc. 2026 Mar; 157(3):224-234.
    View in: PubMed
    Score: 0.209
  13. Oral cancer risk stratification: A cross-sectional population-based screening study in Northeast India. Int J Cancer. 2026 Mar 15; 158(6):1517-1527.
    View in: PubMed
    Score: 0.203
  14. Multistate oral carcinogenesis-A prospective cohort study and a parallel case-control study in Taiwan. Oral Oncol. 2025 03; 162:107210.
    View in: PubMed
    Score: 0.195
  15. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res. 2003 Feb 01; 63(3):555-9.
    View in: PubMed
    Score: 0.169
  16. Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study. J Natl Cancer Inst. 2020 10 01; 112(10):1047-1054.
    View in: PubMed
    Score: 0.144
  17. Understanding the biology of oral cancer and chemoprevention. CDS Rev. 1998 May-Jun; 91(4):24-8.
    View in: PubMed
    Score: 0.122
  18. Molecular markers associated with development and progression of potentially premalignant oral epithelial lesions: Current knowledge and future implications. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 06; 125(6):650-669.
    View in: PubMed
    Score: 0.121
  19. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb; 2(2):209-16.
    View in: PubMed
    Score: 0.104
  20. Assuring dental student head and neck cancer screening competency. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Mar; 111(3):267-8.
    View in: PubMed
    Score: 0.074
  21. Can saliva-based HPV tests establish cancer risk and guide patient management? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Sep; 110(3):273-4.
    View in: PubMed
    Score: 0.071
  22. ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis. Cancer Prev Res (Phila). 2009 Apr; 2(4):385-93.
    View in: PubMed
    Score: 0.065
  23. Oral cancer screening aids: where is the science? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Feb; 103(2):153-4.
    View in: PubMed
    Score: 0.056
  24. Angiogenesis in the development of head and neck cancer and its inhibition by chemopreventive agents. Crit Rev Oral Biol Med. 1999; 10(2):153-64.
    View in: PubMed
    Score: 0.032
  25. Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. J Natl Cancer Inst. 2018 03 01; 110(3).
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.